Cancer mortality according to lipid-lowering drugs and lipoproteins in a general population

Author： Bérard E.   Bongard V.   Dallongeville J.   Arveiler D.   Ruidavets J.B.   Ferrières J.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.27, Iss.10, 2011-10, pp. : 1963-1971

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lipid-lowering drugs as primary prevention in general practice: Do patients reach guideline goals and continue treatment? ADDITION Denmark

By Graversen Lise   Christensen Bo   Borch-Johnsen Knut   Lauritzen Torsten   Sandbaek Annelli  

Scandinavian Journal of Primary Health Care, Vol. 29, Iss. 4, 2011-12 ,pp. : 216-221

Informa Healthcare

Access to resources Recommend Favorite

Lipid-Lowering Drugs: Are Adverse Effects Predictable and Reversible?

By  

Cardiology, Vol. 97, Iss. 3, 2002-06 ,pp. : 115-121

Karger

Access to resources Recommend Favorite

Rapid effects of different lipid-lowering drugs on PCSK9 in humans

By Liu Jun   Guo Yuan-Lin   Xu Rui-Xia   Li Jian-Jun  

Clinical Lipidology, Vol. 8, Iss. 5, 2013-10 ,pp. : 519-524

Future Medicine

Access to resources Recommend Favorite

Why do sales of lipid-lowering drugs vary between counties in Norway?

By Hartz Ingeborg   Njølstad Inger   Furu Kari   Skurtveit Svetlana   Elise Eggen Anne  

Scandinavian Journal of Primary Health Care, Vol. 24, Iss. 2, 2006-06 ,pp. : 115-121

Informa Healthcare

Access to resources Recommend Favorite

The use of lipid-lowering drugs across ethnic groups in the secondary prevention of ischaemic heart disease: analysis of cross-sectional surveys in England

By Gill Paramjit S   Quirke Terry P   Mant Jonathan W   Allan Teresa F  

British Journal of General Practice, Vol. 54, Iss. 503, 2004-06 ,pp. : 442-443

Royal College of General Practitioners

Access to resources Recommend Favorite